Volume | 14,123 |
|
|||||
News | - | ||||||
Day High | 4.00 | Low High |
|||||
Day Low | 3.6501 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aileron Therapeutics Inc | ALRN | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
4.00 | 3.6501 | 4.00 | 3.90 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
179 | 14,123 | $ 3.88 | $ 54,755 | - | 1.01 - 7.42 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:57:14 | 1 | $ 3.85 | USD |
Aileron Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
19.05M | 4.89M | - | 0 | -15.73M | -3.22 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aileron Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALRN Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 3.65 | 4.00 | 3.28 | 3.75 | 58,981 | 0.23 | 6.30% |
1 Month | 5.08 | 7.42 | 3.28 | 4.57 | 211,569 | -1.20 | -23.62% |
3 Months | 4.70 | 7.42 | 3.28 | 4.86 | 94,858 | -0.82 | -17.45% |
6 Months | 1.59 | 7.42 | 1.52 | 4.49 | 99,677 | 2.29 | 144.03% |
1 Year | 1.37 | 7.42 | 1.01 | 3.74 | 65,767 | 2.51 | 183.21% |
3 Years | 21.00 | 28.00 | 1.01 | 10.72 | 313,389 | -17.12 | -81.52% |
5 Years | 28.00 | 49.40 | 1.01 | 22.81 | 625,623 | -24.12 | -86.14% |
Aileron Therapeutics Description
Aileron Therapeutics Inc a clinical-stage biopharmaceutical company. It is focused on developing a novel class of therapeutics for the treatment of cancer and other diseases. The company's lead product candidate, ALRN-6924 is a novel chemoprotective medicine to treat and protect healthy cells in patients with cancer that harbors p53 mutations to reduce or eliminate chemotherapy-induced side effects. |